Three different ICIs, PD‐1 inhibitors, PD‐L1 inhibitors, and CTLA‐4 inhibitors, have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of various cancer types.15 The gene discussed is CD274; the disease is cancer.